Investor Relations
Merrion Pharmaceuticals plc (‘Merrion’) is a speciality pharmaceutical company with operations in Ireland and the United States and is focused on the development of improved oral dosage forms of drugs with poor bioavailability. Merrion, founded in 2003, was formed to acquire a range of assets from Elan Corporation following the announcement that it was re-organising to focus on key therapeutic areas and was electing to dispose of its drug delivery businesses. Merrion is currently developing improved formulations of known drugs, which will allow: (i) the drug to be administered orally when previously it was in injectable form; and/or (ii) improve the bioavailability of an existing oral formulation. The company is developing these enhanced drug profiles using its patented drug delivery platforms GIPET and GIRES. It is also looking to develop the platforms as drug delivery options for companies bringing new drugs to the market.
Recent Releases
Jul 10, 2008
Merrion Pharmaceuticals Appoints Dr John Fox as Chief Development Officer
Events
Jun 24, 2008
Merrion Pharmaceuticals to present at Piper Jaffray Europe Conference, London, UK, Tuesday, June 24, 2008 3:40 PM UKT
Recent Company Presentations
Jun 24, 2008
Merrion Pharmaceuticals Plc Presentation at the Piper Jaffray Europe Conference
Jan 8, 2008
Making Medicines Better
